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HIV-1 coreceptors are attractive targets for novel antivirals. Here, inhibition of entry by two classes of CCR5 antagonists was investigated. We
confirmed previous findings that HIV-1 isolates vary greatly in their sensitivity to small molecule inhibitors of CCR5-mediated entry, SCH-C and
TAK-779. In contrast, an anti-CCR5 monoclonal antibody (PA14) similarly inhibited entry of diverse viral isolates. Sensitivity to small molecules
was V3 loop-dependent and inversely proportional to the level of gp120 binding to CCR5. Moreover, combinations of the MAb and small
molecules were highly synergistic in blocking HIV-1 entry, suggesting different mechanisms of action. This was confirmed by time course of
inhibition experiments wherein the PA14 MAb and small molecules were shown to inhibit temporally distinct stages of CCR5 usage. We propose
that small molecules inhibit V3 binding to the second extracellular loop of CCR5, whereas PA14 preferentially inhibits subsequent events such as
CCR5 recruitment into the fusion complex or conformational changes in the gp120-CCR5 complex that trigger fusion. Importantly, our findings
suggest that combinations of CCR5 inhibitors with different mechanisms of action will be central to controlling HIV-1 infection and slowing the
emergence of resistant strains.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1; CCR5; Coreceptor; Entry; Inhibitors; Small molecules; Monoclonal antibodies; Synergy; V3 loopIntroduction
The two physiologically relevant HIV-1 entry coreceptors
are the 7 transmembrane spanning G-coupled chemokine
receptors CCR5 and CXCR4. CCR5 is considered a prime
target for novel antivirals because it does not appear to be
essential for normal immune function (Carrington et al., 1997;
Liu et al., 1996). Numerous small molecule CCR5 antagonists
and anti-CCR5 monoclonal antibodies (MAbs) have been
characterized, and some are in clinical development (reviewed
in Seibert and Sakmar, 2004). It has been shown that from the
outset, HIV-1 strains differ significantly in their sensitivity to
small molecule antagonists such as SCH-C and TAK-779⁎ Corresponding author. Fax: +1 718 430 8711.
E-mail address: tdragic@aecom.yu.edu (T. Dragic).
1 The authors have contributed equally to this study.
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.05.016(Rusert et al., 2005; Strizki et al., 2001; Trkola et al., 2002).
Moreover, resistant strains are generated rapidly in vitro by
evolving to use inhibitor-occupied CCR5 (Kuhmann et al.,
2004; Marozsan et al., 2005). Resistance to an anti-CCR5 MAb
has also been described, but the mechanism remains unclear
(Aarons et al., 2001). As with all HIV-1 antivirals, therefore,
this new class of inhibitors may be limited by variable efficacy
and the emergence of resistant strains.
HIV-1 entry into target cells is mediated by a cascade of
binding and conformational events (reviewed in Berger et al.,
1999; Weiss, 2003). The virus attaches to the cell surface by
binding the CD4 receptor, which induces a coreceptor binding
site on gp120. There are at least two contact points between
gp120 and the CCR5 coreceptor, which may be established in
temporally distinct stages (reviewed in (Hartley et al., 2005)).
The second extracellular loop (ECL2) of CCR5 probably
interacts with the crown of the gp120 V3 loop whereas the
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bridging sheet (Cormier and Dragic, 2002; Cormier et al., 2001;
Hartley et al., 2005). Once the gp120-coreceptor complex
attains its final conformation, including dissociation of the
gp120/gp41 heterodimer (Abrahamyan et al., 2003; Binley et
al., 2003), it triggers the gp41 membrane fusion machinery
(reviewed in LaBranche et al., 2001).
We have previously shown that small molecules SCH-C and
TAK-779 bind to a pocket in the transmembrane domain of
CCR5 and non-competitively block gp120 binding to the
coreceptor (Dragic et al., 2000; Tsamis et al., 2003). We also
determined that neither SCH-C nor TAK-779 inhibit the gp120
interaction with the Nt (Cormier et al., 2001). Both molecules,
however, block binding of several monoclonal antibodies that
recognize epitopes in the second extracellular loop of CCR5
(Tsamis et al., 2003). Based on these and other findings, we had
proposed that the small molecules alter the conformation of
ECL2 such that it is no longer recognized by the V3 crown.
Reeves et al. showed that the V3 loop modulates sensitivity to
TAK-779 (Reeves et al., 2002). Kuhmann et al. described the
gp120 of a SCH-C-resistant isolate that sustained multiple
substitutions in the V3 crown, leading to a reduced affinity for
CCR5 and an increased affinity for the CCR5 inhibitor complex
(Kuhmann et al., 2004). The data from these groups therefore
support the model that small molecule compounds disrupt
CCR5 interactions with the V3 loop by an allosteric
mechanism.Fig. 1. Sensitivity of primary isolates to SCH-C and PA14. (A) Target cells (He
envelope glycoproteins of thirteen different isolates in the presence of a range of
values for each combination of compound and isolate. Values are means of three
HIV-1 pseudotypes comprising envelope glycoproteins of JR-FL, 92NG083 or 93T
or (D) PA14. Luciferase activity in cell lysates was determined 48 h post-infection
(RLU in the absence of inhibitor) × 100. The three isolates generated similar RLU
experiment.Numerous anti-CCR5 monoclonal antibodies (MAbs) have
been described (Lee et al., 1999; Olson et al., 1999; Wu et al.,
1997). The mechanism of entry inhibition by anti-CCR5 MAbs,
however, is not well understood. We had previously shown that
MAbs that recognize epitopes in the CCR5 Nt efficiently block
gp120 binding to the coreceptor but do not potently inhibit viral
entry (Olson et al., 1999). In contrast, two MAbs with epitopes
lying in ECL2 are poor inhibitors of gp120 binding but highly
efficient inhibitors of viral entry (Olson et al., 1999). We had
suggested that these MAbs inhibit important post-gp120
binding steps, such as conformational changes in CCR5 or its
oligomerization (Kuhmann et al., 2000). Notably, resistance to
one of these anti-CCR5 MAbs (2D7) does not appear to map to
a particular region of gp120 and its mechanism remains unclear
(Aarons et al., 2001).
In this study, we explored inhibition of HIV-1 entry by two
small molecules and an anti-CCR5 MAb. Envelope glycopro-
teins from a panel of primary isolates were used to generate
reporter pseudoviruses and inhibition of entry was tested in
HeLa-CD4-CCR5 cells. We thus showed that sensitivity to
SCH-C and TAK-779 over four orders of magnitude in our
experimental system. In contrast, sensitivity of the same isolates
to inhibition by an anti-CCR5 MAb (PA14) varied by no more
than six-fold. Sensitivity to the small molecules was dependent
on gp120 affinity for CCR5, and this was regulated by the V3
loop crown. Combinations of PA14 and SCH-C or TAK-779
were synergistic in blocking HIV-1 entry. The PA14 MAb wasLa-CD4-CCR5) were infected with HIV-1 reporter viruses pseudotyped with
inhibitor concentrations. Non-linear curve fitting was used to determine IC50
independent experiments. Target cells (HeLa-CD4-CCR5) were infected with
H966 in the presence of different concentrations of (B) SCH-C, (C) TAK-779
and % HIV-1pp entry was calculated as (RLU in the presence of inhibitor)/
values in the absence of inhibitor, ranging from 104 to 106 depending on the
Fig. 2. Inhibition of entry mediated by chimeric envelope glycoproteins with
small molecules. (A) Amino acid differences between the V3 loops of JR-FL,
92NG083 and 93TH966 are in bold. The V3 crown is outlined. Target cells
(HeLa-CD4-CCR5) were infected with HIV-1 pseudotypes comprising chimeric
envelope glycoproteins JR-FL(92NG083), 92NG083(JR-FL) or 93TH966(JR-
FL) in the presence of different concentrations of (B) SCH-C or (C) TAK-779.
Luciferase activity in infected cells was determined 48 h post-infection and %
HIV-1pp entry was calculated as (RLU in the presence of inhibitor)/(RLU in the
absence of inhibitor) × 100. Like the wild-type envelope glycoproteins, the
chimeras also generated similar RLU values in the absence of inhibitor, ranging
from 104 to 106.
479D. Safarian et al. / Virology 352 (2006) 477–484found to inhibit CCR5 usage at a stage following the one that is
sensitive to inhibition by the small molecules, and preceding
gp41-triggered membrane fusion.
Results
Small molecule SCH-C and anti-CCR5 MAb PA14 exhibit
different patterns of HIV-1 entry inhibition
We compared the abilities of small molecule antagonists
SCH-C and TAK-779 as well as anti-CCR5 MAb PA14 to
inhibit entry of HIV-1 reporter viruses pseudotyped with the
envelope glycoproteins of thirteen primary R5 isolates (HIV-
1pp). The readout of our assay was luciferase activity (relative
light units, RLU) in target cell lysates (HeLa-CD4-CCR5),
which is directly proportional to HIV-1pp entry. Importantly, the
percentage of inhibition by the anti-CCR5 compounds was
independent of the starting levels of entry when these were
between 104 and 106 RLU, meaning that we were working
within the linear range of the assay. Note that the standard
deviation of our entry assay is ±20%.
Half-maximal inhibitory concentrations for SCH-C (IC50)
ranged over four orders of magnitude, between 2.9 × 10−12 M
and 2.1 × 10−8 M (Fig. 1A). The mean IC50 for our set of test
isolates was 6.8 × 10−9 M. Similarly, TAK-779 IC50s ranged
between 1.0 × 10−11 M and 1.1 × 10−7 M with a mean of
2.9 × 10−8 M. Partial overlap of SCH-C and TAK-779
binding sites on CCR5 probably explains this similarity. In
contrast, the IC50 values for PA14 were constrained within a
single order of magnitude and varied between 1.2 × 10−9 M
and 6.9 × 10−9 M, with a mean of 4.0 × 10−9 M (Fig. 1A).
The differences in IC50 variances between PA14 and SCH-C
as well as PA14 and TAK-779 were highly significant
(P < 0.0001 as determined by a F test).
From the initial set of thirteen test isolates, three were chosen
for further studies. Entry mediated by envelope glycoproteins of
92NG083 and 93TH966 was similarly sensitive to all anti-
CCR5 compounds whereas JR-FL-mediated entry was less
sensitive to the small molecules (Figs. 1B–D). The IC50s for
SCH-C were 4.5 × 10−9 M for JR-FL, 8.2 × 10−10 M for
92NG083 and 8.0 × 10−10 M for 93TH966 (Fig. 1B). Likewise,
TAK-779 exhibited similar IC50s for 92NG083 and 93TH966,
which were 2.4 × 10−9 M and 3.1 × 10−9 M respectively (Fig.
1C). JR-FL was also less sensitive to TAK-779 with an IC50 of
2.0 × 10−8 M. JR-FL was therefore approximately five times
less sensitive to SCH-C and eight times less sensitive to TAK-
779 than 92NG083 and 93TH966. In contrast, PA14 IC50 values
were 1.9 × 10−9 M for JR-FL, 1.3 × 10−9 M for 92NG083, and
1.0 × 10−9 M for 93TH966 (Fig. 1D). These values were not
statistically different.
The V3 loop crown determines sensitivity to SCH-C and
TAK-779
Based on previous findings by us and others, we hypothe-
sized that the gp120 V3 loop would be the major determinant of
HIV-1 sensitivity to small molecule inhibitors. Using pair-wisealignment, we determined that JR-FL and 92NG083 V3 loops
are 86% identical and 94% similar. Differences include a T→ I
at the first position of the amino-terminal arm of the stem, as
well as H→ P, R→ Q, T→ A and E→ D in the crown (Fig.
2A). JR-FL and 92TH966 V3 loops are 67% identical and 80%
similar and differ by ten residues, including a I → T, H → T,
R→ Q, A→ V, T→ R and E→ D in the crown (Fig. 2A). We
note that the majority of V3 loop differences map to the crowns.
Envelope glycoprotein chimeras were generated to test the role
of these differences in sensitivity to small molecule inhibitors.
The V3 loop of JR-FL gp120 was substituted for the V3 loop
of 92NG083 to generate the chimera JR-FL(92NG083).
Likewise, the V3 loop of 92NG083 was substituted for that of
JR-FL to generate 92NG083(JR-FL). We also generated
93TH966 gp120 bearing the V3 crown of the JR-FL isolate.
Inhibition by SCH-C and TAK-779 of HIV-1pp entry mediated
by full-length chimeric envelope glycoproteins was measured.
SCH-C inhibited entry mediated by JR-FL(92NG083) with an
480 D. Safarian et al. / Virology 352 (2006) 477–484IC50 of 8.1 × 10
−10 M, whereas entry mediated by 92NG083
(JR-FL) and 93TH966(JR-FL) was inhibited similarly, with
IC50s of 8.5 × 10
−9 M and 9.2 × 10−9 M, respectively (Fig. 2B).
Likewise, TAK-779 inhibited entry mediated by JR-FL
(92NG083) more efficiently than entry mediated by 92NG083
(JR-FL) and 93TH966(JR-FL): IC50 values of 2.1 × 10
−9 M,
4.8 × 10−8 M and 5.0 × 10−8 M, respectively (Fig. 2C).
Switching V3 loops therefore switches sensitivity phenotypes to
small molecule inhibitors because JR-FL bearing the V3 loop of
92NG083 is inhibited similarly to wild-type 92NG083.
Likewise, 92NG083(JR-FL) and 93TH966(JR-FL) acquire the
JR-FL sensitivity phenotype. Our observations confirm that
differences in sensitivity to small molecules between these three
isolates can be entirely attributed to differences in the V3 loop
and especially its crown.
The V3 crown modulates gp120 affinity for CCR5
We next determined how the V3 loop modulates sensitivity
to small molecule inhibitors SCH-C and TAK-779. For this, JR-
FL, 92NG083, JR-FL(92NG083) and 92NG083(JR-FL) soluble
gp120 proteins were generated by transient transfection of 293T
cells and quantified in supernatants by Western blotting and
ELISA (Fig. 3A and data not shown). Binding of the envelopeFig. 3. Binding of wild-type and chimeric gp120 proteins to CCR5. (A) 293T cells w
including JR-FL, 92NG083, JR-FL(92NG083) and 92NG083(JR-FL). Gp120 in supe
was confirmed byWestern blotting with the B12MAb. (B) CCR5-expressing L1.2 ce
supernatants (dotted line) or supernatants comprising different gp120 proteins (40 μg
with a PE-labeled goat anti-human IgG2 antibody (1:100).glycoproteins to CD4-IgG2 as measured by ELISA was
comparable (data not shown). Binding of gp120/CD4-IgG2
complexes to CCR5-positive L1.2 cells was measured by flow
cytometry, as previously described by us (Dragic et al., 1998).
Background MFI levels, measured with mock-transfected
supernatants and CD4-IgG2, ranged between 2 and 4. Similar
values were obtained when parental L1.2 cells were used in the
binding assay (data not shown).
At similar concentrations of soluble envelope proteins
(∼40 μg/ml), JR-FL gp120 binding generated a mean
fluorescence intensity (MFI) of 620 (Fig. 3B). In contrast,
gp120 of 92NG083 exhibited very weak binding with anMFI of
only 20. The CCR5-binding phenotype of the chimeric gp120
proteins was completely inversed. In other words, 92NG083
(JR-FL) bound CCR5 to the same extent as JR-FL gp120 (MFI
of 560) (Fig. 3B). In contrast JR-FL gp120 bearing the V3 loop
of 92NG083 exhibited a profound loss of binding activity and
now behaved like 92NG083 gp120 (MFI of 25) (Fig. 3B). Note
that the MFI values obtained with 92NG083 and JR-FL
(92NG083) gp120 were low, thereby limiting the dynamic
range of the assay and making it difficult to generate a reliable
binding curve. Nonetheless, our results clearly demonstrate a
difference in CCR5 binding of the four gp120 proteins and
indicate that the higher sensitivity of 92NG083 to SCH-C andere transiently transfected with constructs expressing different gp120 proteins,
rnatants were quantified by ELISA and adjusted to the same concentration, which
lls were incubated with CD4-IgG2 (20 μg/ml) mixed with mock-transfected 293T
/ml) (solid line). Binding to CCR5 was detected by flow cytometry after labeling
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is regulated by the V3 loop crown.
Small molecules and anti-CCR5 MAb PA14 inhibit distinct
stages of CCR5 usage
Synergy studies were performed by investigating inhibition
of entry mediated by the envelope glycoproteins of the JR-FL
isolate with combinations of SCH-C or TAK-779 and PA14Fig. 4. Time course of inhibition of HIV-1 entry with SCH-C, PA14 and T20. (A, B)
Target cells (HeLa-CD4-CCR5) were infected with HIV-1 pseudotypes comprising
envelope glycoproteins of JR-FL in the presence of different concentrations of SCH-
C, TAK-779, PA14 or equimolar combinations of small molecules and PA14.
Luciferase activity in cell lysates was determined 48 h post-infection and%HIV-1pp
entry was calculated as (RLU in the presence of inhibitor)/(RLU in the absence of
inhibitor) × 100. (C) JR-FL pseudoparticles were pre-bound to target cells (HeLa-
CD4-CCR5) at 4 °C by spinoculation. After washing, cells were warmed to 37 °C
and inhibitors added at different time points. Luciferase activity in infected cells was
determined 48 h post-infection and %JR-FLpp entry was calculated (RLU with
inhibitor at n′)/(RLUwithout inhibitor) × 100.Values aremeans of three independent
experiments ±SD.(Figs. 4A, B). Data were analyzed by the median effect
principle (Chou and Rideout, 1991). The concentrations of
single agents or their mixtures required to produce a given
effect were quantitatively compared in a term known as the
Combination Index (CI). A CI value greater than 1 indicates
antagonism, CI ∼1 indicates an additive effect, and CI <1
indicates a synergistic effect wherein the presence of one agent
enhances the effect of another. We found that at 90% entry
inhibition the CI index for SCH-C and PA14 was 0.17, whereas
at 50% entry inhibition the CI index was 0.063 (Table 1).
Similarly, the CI indices for TAK-779 and PA14 were 0.57 and
0.25 at IC90 and IC50 respectively (Table 1). Combinations of
small molecules and PA14 therefore synergistically inhibit JR-
FL envelope-mediated entry. This suggests that the compounds
act through different mechanisms.
To determine whether the small molecule inhibitor SCH-C
and PA14 inhibit different stages of HIV-1 entry, we performed
time course of inhibition experiments with the two compounds
as well as with T20, an inhibitor of gp41-mediated fusion.
Briefly, HIV-1pp comprising the JR-FL envelope glycoprotein
was spinoculated onto target cells at 4 °C for 1 h. Unbound
particles were removed by washing and inhibitors at IC90
(3 × 10−9 M PA14, 3 × 10−8 M SCH-C and 3 × 10−8 M of T20)
or medium were added at 37 °C in order to initiate synchronized
viral entry and define a t = 0. Inhibitors were then added at
different time points until 3 h post-t = 0. The time required for
half maximal inhibition (t1/2) of JR-FL pseudotype entry by
SCH-C was 9 min (Fig. 4C). For PA14, however, the t1/2 was
32 min, meaning that there is a 23-min lag between the stage
inhibited by SCH-C and the stage inhibited by PA14. Finally,
the t1/2 of inhibition of gp41-mediated membrane fusion by T20
occurred within 46 min, marking it as the end-point of HIV-1
entry. Similar results, with slightly slower kinetics, were
obtained for the 92NG083 isolate (data not shown). Note that
t1/2 values were calculated using one-phase exponential
association curve fitting.
Discussion
In this study, we characterized the mechanism of inhibition
of HIV-1 entry by small molecule CCR5 antagonists and an
anti-CCR5MAb. Inhibition of entry of a panel of HIV-1 isolates
ranged over four orders of magnitude for SCH-C and TAK-779.
In contrast, PA14 IC50 values varied by no more than six-fold
for the same set of isolates. A comparison of PA14 and SCH-C
IC50 values in a scatter plot showed a weak correlation between
the two sets of values (P = 0.0315 using Pearson's r test). In
other words, isolates that were more sensitive to SCH-C also
tended to be more sensitive to PA14. This correlation, however,
was completely lost (P = 0.6593) when the three isolates least
sensitive to SCH-C (IC50 values ≥10−8 M) were removed from
calculations of the linear regression curve. In contrast, a very
strong correlation was found between sensitivity to SCH-C and
sensitivity to TAK-779 (P < 0.0001). Together, these analyses
gave the first indication that small molecule CCR5 antagonists
and the anti-CCR5 MAb PA14 inhibit HIV-1 entry by different
mechanisms.
Table 1
CI values based on fixed ratio compound combinations
IC50 IC90
SCH-C + PA14 0.06 0.17
TAK-779 + PA14 0.25 0.57
The concentrations of single agents or combinations required to produce half-
maximal and 90% inhibition of HIV-1 entry were quantitatively compared in a
term known as the combination index (CI). Synergism is defined as a greater-
than-expected-additive effect, and antagonism is defined as less-than-expected-
additive effect.
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85% similar to both 92NG083 and 93TH966 sequences. Using
gp120 chimeras, we demonstrated that the difference in
sensitivity to small molecule CCR5 antagonists is directly
regulated by the V3 loops, especially the crown regions, of our
three test isolates. Moreover, we showed that the V3 loop
directly modulates the level of gp120 binding to CCR5 and that
low binding correlates with high sensitivity to SCH-C and
TAK-779. In other words, a gp120 that interacts weakly with
CCR5 is more easily displaced from the coreceptor in the
presence of the inhibitors. A similar conclusion was reached by
Reeves et al. using various gp120 V3 loop chimeras (Reeves et
al., 2002). This group also showed that gp120 affinity for CCR5
directly affects the kinetics of viral entry (Reeves et al., 2002,
2004). Our findings further support the model wherein the
crown of the V3 loop interacts with ECL2 of CCR5, thereby
determining the efficiency of entry inhibition.
In contrast to the small molecules, inhibition of entry by
anti-CCR5 MAb PA14 was similar for all test isolates and
not a function of gp120 affinity or V3 loop sequence. We
had previously shown that PA14 was approximately 10-fold
less potent at inhibiting gp120 binding than anti-CCR5
MAbs that target the Nt. Conversely, PA14 was 10-fold
more potent than these MAbs at inhibiting viral entry (Olson
et al., 1999). Here, we demonstrated that PA14 inhibits a
step in CCR5 usage that comes after the step inhibited by
the small molecule antagonists and before gp41-mediated
membrane fusion. The PA14 epitope has an unusual
configuration in that it comprises both the first residue of
the Nt (D2) and the first residue of ECL2 (R169) at the
junction of ECL2 and TM4 (Olson et al., 1999). When
bound to CCR5, therefore, this MAb may lie close and
parallel to the plasma membrane and preferentially inhibit
gp120-independent events, for example, oligomerization of
CCR5 within a fusion complex.
Based on our findings, we propose the following model of
HIV-1 entry and inhibition: the V3 crown–ECL2 interaction is
the very first step in CCR5 usage; 9 min elapse between CD4
binding and V3 crown–ECL2 interactions. Small molecule
antagonists such as SCH-C and TAK-779 disfigure CCR5 ECL2
making it unrecognizable by the gp120V3 loop crown. Based on
our previous work, we propose that the second step to occur is
the interaction between the CCR5 Nt and the V3 stem/bridging
sheet. This stage of coreceptor usage is weakly inhibited by
MAbs that recognize the CCR5 Nt, probably due to poor epitope
accessibility in the context of the gp120-CCR5 complex during
viral entry (Olson et al., 1999). Once gp120 is firmly tethered to
CCR5, further conformational changes, protein modifications or
oligomerization can occur. We propose that these are blocked by
PA14 and that together with the second stage of entry they occur
over 23 min. Another 14 min is required for maturation of the
CCR5-gp120 complex, including gp120-gp41 dissociation,
resulting in gp41-mediated membrane fusion. Note that the t1/
2s we measure are not absolute and depend on the concentrations
of receptors and envelope glycoproteins, as well as the relative
affinities of these proteins for each other. However, a similar
distribution of Δt1/2s was measured for isolate 92NG083 (T.D.,unpublished results), suggesting that the different stages of entry
are common to all HIV-1 isolates. Combinations of SCH-C and
PA14 are highly synergistic inhibitors because they target
different stages of HIV-1 entry.
Our data also have implications regarding the emergence
of resistant HIV-1 isolates. The V3 loop is one of the most
variable regions of gp120, and it should therefore be expected
that strains resistant to small molecule inhibitors such as
SCH-C and TAK-779 will appear relatively quickly. Whether
these isolates will remain R5, as suggested by Kuhmann et
al., or resort to CXCR4 usage in vivo remains to be seen. On
the other hand, we would predict that HIV-1 will have
difficulty developing resistance to MAbs such as PA14 since
this compound does not (primarily) inhibit the CCR5-gp120
interaction but preferentially inhibits post-binding steps.
Future drug discovery programs should therefore strive to
develop screens for identifying small molecules with similar
properties. We recognize that this may be difficult as small
molecules tend to act through allosteric mechanisms rather
than by sterically blocking interactions. Ultimately, com-
pounds such as PA14 or small molecules with differing
cooperativity factors will stand the best chance of retaining
long-term effectiveness in the clinic.
Materials and methods
Cell lines, antibodies and inhibitors
HeLa-CD4-CCR5 cells (Vodicka et al., 1997) were cultured in
standardDMEM-basedmedium supplementedwithG418 (800μg/
ml). L1.2-CCR5 cells (Wu et al., 1996) were cultured in RPMI-
based medium supplemented with β-mercaptoethanol (100 μM)
andG418 (800μg/ml). CD4-IgG2 and anti-CCR5MAbPA14were
generated by Progenics Pharmaceuticals, Inc. (Tarrytown, NY) as
described previously (Allaway et al., 1995; Olson et al., 1999).
Anti-gp120 MAb B12 (Moore et al., 1994) was generously
provided by Dr. William Olson (Progenics Pharmaceuticals). The
small-molecule CCR5 antagonists SCH-C and TAK-779 were
synthesized as described previously (Tsamis et al., 2003). T20 was
synthesized by American Peptide according to the described
sequence (Kilby et al., 1998; Matthews et al., 2004).
Single cycle HIV-1 entry assay
NLluc+env− pseudoparticles were made as described (Dragic
et al., 1998), using HIV-1 envelope glycoproteins from the
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ADA (Westervelt et al., 1991), BaL (Hwang et al., 1992),
93MW960, 92BR025, 93MW965, 92RW020, 93TH966 (Gao
et al., 1996), 94IN476, 98IN012 (Rodenburg et al., 2001),
94NG114, 92NG083 (Gao et al., 1998), as well as chimeric
envelope glycoproteins JR-FL(92NG083) and 92NG083(JR-
FL) (see below). Hela-CD4-CCR5 target cells (4 × 104) were
incubated with virus-containing supernatants (100 ng/ml p24),
plus or minus different concentrations of inhibitors for 16 h
before medium was changed. After 48 h, cells were lysed, and
luciferase activity (relative light units, RLU) was measured
using a standard kit (Promega) as described (Dragic et al.,
1998).
Synergy studies were performed with fixed-ratio compound
combinations. Target cells were treated either with individual
anti-CCR5 compounds or with equimolar mixtures of PA14 and
SCH-C or TAK-779, followed by infection with JR-FL
pseudotypes. The concentrations of single agents or combina-
tions required to produce half-maximal and 90% inhibition of
HIV-1 entry were quantitatively compared in a term known as
the Combination Index (CI). The CI method is based on the
median-effect principle described by Chou (for review, see
Reynolds and Maurer, 2005). We developed our own software
to calculate CI values (Olson et al., 1999). D = Dm [fa/fu]
1/m,
where D is compound concentration, Dm is the median-effect
dose (IC50), fa is the fraction of the response affected by the
dose, and fu = 1 − fa. CI for any given fa value is then calculated
as (D1combo/D1single) + (D2combo/D2single) + (D1combo
* D2combo/
D1single
* D2single).
For time course of inhibition experiments, HIV-1 pseudo-
particles were chilled on ice, added to cells and spinoculated for
1 h at 2000 rpm at 4 °C. Cells were washed twice with PBS at
4 °C and medium at 37 °C, containing PA14 (3 × 10−9 M),
SCH-C (3 × 10−8 M) or T20 (3 × 10−8 M) was added at different
time points, from 0 to 3 h. After addition of MAbs, cells were
kept at 37 °C for the duration of the experiment. Medium was
changed 16 h after the first time point of inhibitor addition
(t = 0). Luciferase activity was measured in cell lysates 48 h
post-infection.
Generation of V3 loop chimeras
Chimeric gp120 proteins were generated by substituting
V3 loop residues using the QuickChange Kit (Stratagene).
Nucleotide sequencing was performed to ascertain the
presence of the appropriate substitutions. Envelope glycopro-
tein sequences in the SV7D expression vector served as
templates and were used to generate pseudoparticles com-
prising chimeric glycoproteins. Wild-type and chimeric gp120
sequences were also subcloned into the PPI4 expression
vector for generating soluble proteins (Binley et al., 2000).
Supernatants containing wild-type and mutant gp120 proteins
were generated by transient transfection of 293T cells as
described previously (Binley et al., 2000). Soluble gp120 was
quantified by ELISA and verified by Western blotting with
the B12 anti-gp120 MAb (0.5 μg/ml) as described (Cormier
et al., 2001). Soluble gp120 proteins were also characterizedfor CD4-IgG2 binding as described previously (Cormier et al.,
2001).
Binding of gp120/CD4-IgG2 complexes to cell-surface CCR5
L1.2-CCR5 cells (5 × 105) were incubated with gp120-
containing supernatant (4 × 10−7 M) and CD4-IgG2 (2 ×
10−7 M) for 1 h at 37 °C, as described previously (Olson et al.,
1999). Gp120/CD4-IgG2 bound to cells was revealed by flow
cytometry analysis of the mean fluorescence intensity (MFI)
after addition of a phycoerythrin-conjugated goat anti-human
IgG2 (Pharmingen).
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